Impact of concomitant cardiovascular diseases on functional status and quality of life of patients with Chronic Obstructive Pulmonary Diseases

Kchaou, Khouloud; Kammoun, Rim; Chaabouni, M. M.; Trabelsi, Hana; Triki, Leila; Kammoun, Inès; Zouari, Héla; Masmoudi, Kaouthar

doi:10.1183/13993003.congress-2019.pa4489

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recurrent COPD exacerbations and resultant lung function decline lead to increased cardiovascular risk and mortality [ 58 , 59 ]. Vice versa, patients with COPD and cardiac diseases are more likely to exacerbate versus patients with COPD alone [ 60 ].…”

Section: Methodsmentioning

confidence: 99%

“…A COPD patient with an AECOPD episode is at a higher risk of stroke as compared to patient with COPD and no exacerbation episode (hazard ratio, 6.66; 95% confidence interval, 2.42–18.20) [ 68 ]. Acute episode of AECOPD leads to systemic hypoxia, increased arterial stiffness, and increased systemic inflammation [ 58 , 60 , 61 ]. Hypoxia during AECOPD contributes to endothelial damage and, along with increased thrombogenic inflammatory mediators, may lead to vascular abnormalities and adverse cardiovascular outcomes ( Figure 2 ) [ 58 , 61 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases

Deshmukh

Khanna

2021

Tuberc Respir Dis

View full text Add to dashboard Cite

Globally, cardiovascular diseases and Chronic Obstructive Pulmonary Disease (COPD) are the leading causes of non-communicable disease burden. Overlapping symptoms such as breathlessness and fatigue, coupled with a lack of awareness about COPD among physicians, are important reasons for under-diagnosis and resultant sub-optimal care in COPD. Much has been published earlier on the pathogenesis and implications of cardiovascular comorbidities in COPD. However, a comprehensive review of prevalence and the impact of COPD management in commonly encountered cardiac diseases is lacking. This study aimed at summarizing the current knowledge regarding the prevalence of COPD in heart failure, ischemic heart disease, and atrial fibrillation. We have also discussed the real-life clinical presentation and practical implications of managing COPD in cardiac diseases. We searched Pubmed, Scopus, EMBASE, and Google Scholar for studies published between 1981 to May 2020 reporting the prevalence of COPD in the three specified cardiac diseases. COPD has a high prevalence in heart failure, atrial fibrillation, and ischemic heart disease. Despite this, COPD remains under-diagnosed and under-managed in the majority of patients with cardiac diseases. Clinical implications of the diagnosis of COPD in cardiac disease includes recognition of hyperinflation (a treatable trait), implementation of AECOPD prevention strategies, and reducing the risk of overuse of diuretics. Pharmacological agents for the management of COPD have shown a beneficial effect on cardiac functions and mortality. Appropriate management of COPD improves the cardiovascular outcomes by reducing hyperinflation and preventing AECOPD, thereby reducing the risk of mortality, improving exercise tolerance, and quality of life.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases

Deshmukh

Khanna

2021

Tuberc Respir Dis

View full text Add to dashboard Cite

show abstract

Efficacy of perindopril/amlodipine and valsartan/amlodipine combinations in patients with a combination of arterial hypertension and chronic obstructive pulmonary disease

Bubnova

Kryuchkova

Ицкова

et al. 2022

jour

View full text Add to dashboard Cite

Objective: to study the comparative efficacy and safety of the use of perindopril/amlodipine and valsartan/amlodipine combinations in patients with a combination of arterial hypertension and chronic obstructive pulmonary disease. Materials and methods: 85 patients with a verified diagnosis of arterial hypertension and chronic obstructive pulmonary disease were examined, the average age of patients was 60.9±1.1 years; 54% of men and 46% of women who were prescribed two variants of combination therapy (group A amlodipine/perindopril, group B amlodipine/valsartan). At the first visit and 6 weeks after the start of therapy, all patients underwent clinical, laboratory and instrumental examinations in accordance with the current protocols for the treatment of hypertension and chronic obstructive pulmonary disease, a daily blood pressure study, the frequency of depressive disorders was assessed on the Beck scale and the quality of life according to the SF-36 questionnaire. Results: the use of both antihypertensive regimens in comorbid patients was accompanied by comparable antihypertensive efficacy of therapy, contributed to the same statistically significant decrease in daily, day and night blood pressure indicators. The analysis of the indicators of the function of external respiration revealed the absence of negative dynamics of spirographic indicators in both groups. The use of both combinations of antihypertensive drugs contributed to the statistically identical recovery of both physical and mental components of the patient's quality of life. The improvement in the quality of life of comorbid patients was accompanied by a decrease in the manifestations of depressive disorders in the studied patients according to the Beck scale. The average score of the Beck scale in patients of group A before treatment was 11.6±0.97, against the background of therapy — 9.1±0.77, p <0.001. In patients of group B, it decreased from 13.0±1.06 to 9.3±0.78, p <0.001. Conclusion: the use of antihypertensive combined strategies amlodipine / perindopril and amlodipine / valsartan for the treatment of hypertension in patients with chronic obstructive pulmonary disease is characterized by comparable effectiveness of blood pressure control, which is confirmed by the data of daily monitoring of blood pressure. Effective control of blood pressure was accompanied by statistically significant (p<0.001) positive dynamics of most indicators of the quality of life of patients in both study groups and the severity of manifestations of depression. Any of the studied combinations, which demonstrated comparable efficacy and tolerability in the study, can be recommended as the first step of antihypertensive therapy in patients with arterial hypertension in combination with chronic obstructive pulmonary disease.

show abstract

Impact of concomitant cardiovascular diseases on functional status and quality of life of patients with Chronic Obstructive Pulmonary Diseases

Cited by 2 publications

References 0 publications

Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases

Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases

Efficacy of perindopril/amlodipine and valsartan/amlodipine combinations in patients with a combination of arterial hypertension and chronic obstructive pulmonary disease

Contact Info

Product

Resources

About